Deutsche Bank Maintains Buy on 10x Genomics, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Justin Bowers maintains a Buy rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $60 to $55.

April 18, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Deutsche Bank maintains a Buy rating on 10x Genomics but reduces the price target from $60 to $55.
The adjustment in price target by a major bank like Deutsche Bank reflects a nuanced view on 10x Genomics' valuation, suggesting a positive outlook albeit with a slightly reduced growth expectation. This could lead to mixed short-term reactions in the market, balancing between the continued endorsement via a Buy rating and the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100